Evidence map›Paper›PMID 42131372›Full record

ArticleJournal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada2026

Carbapenemase-producing hypervirulent

Romaine Edirmanasinghe, Tanis C Dingle, Matthew A Croxen, David A Boyd, Laura Mataseje

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. HypervirulentOpen forum infectious diseases · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Romaine EdirmanasingheAntimicrobial Resistance and Nosocomial Infections, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
Tanis C DingleAlberta Precision Laboratories Public Health Laboratory, Calgary, Alberta, Canada.
Matthew A CroxenAlberta Precision Laboratories Public Health Laboratory, Edmonton, Alberta, Canada.
David A BoydAntimicrobial Resistance and Nosocomial Infections, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
Laura MatasejeAntimicrobial Resistance and Nosocomial Infections, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hypervirulent Methods: Carbapenemase-producing Results: Eight different sequence types (ST) were observed among the 16 cases identified, including several global high-risk lineages (ST11, ST15, ST231, ST147, and ST395) and one hypervirulent lineage (ST23). Carbapenemase genes included Conclusion: These data highlights the presence of high-risk lineages of hvKp in the Canadian landscape, as well as the first report of ST23 in Canada.

Indexed as

antimicrobial resistancebacterial infectionscarbapenemase-producing EnterobacteriaceaeKlebsiella sp

Identifiers

PMID42131372
PMCPMC13167180

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.